Gismo Therapeutics

Gismo Therapeutics Inc. is a biotech start-up company targeting fundamental biochemical processes that are at the root cause of Alzheimer’s and Parkinson’s Disease pathogenesis. The company has been awarded several prestigious research grants to further develop its industry-leading technology, GISMO, which is associated with a new hypothesis of the etiology of major neurodegenerative amyloid diseases. Gismo Therapeutics Inc. is developing first-in-class, disease-modifying oral therapeutics for the treatment of both Alzheimer’s Disease, and Parkinson’s Disease.